NASDAQ: ZTEK
Zentek Ltd Stock

$1.18+0.20 (+20.41%)
Updated Jan 17, 2025
ZTEK Price
$1.18
Fair Value Price
$0.01
Market Cap
$122.80M
52 Week Low
$0.50
52 Week High
$1.48
P/E
-13.72x
P/B
9.19x
P/S
2,484.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$28.31k
Earnings
-$7.90M
Gross Margin
-1,038.8%
Operating Margin
-26,520.77%
Profit Margin
-27,291.7%
Debt to Equity
0.15
Operating Cash Flow
-$5M
Beta
0.68
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ZTEK Overview

Zentek Limited researches and develops graphene and related nanomaterials. It owns 100% interest in the Albany Graphite Project located in Northern Ontario, Canada. The company develops antimicrobial coating and surgical masks, HVAC filters, and personal protective equipment. It is also developing synthesized graphene, graphene oxide, and graphene quantum dots. The company was known as ZEN Graphene Solutions Ltd. until 2021/10. Zentek was founded in 2008 and is headquartered in Thunder Bay, Canada.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ZTEK's potential to beat the market

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
B
ZTEK
Ranked
Unranked of 49

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$44.35A
$7.98A
$18.68A
View Top Medical Stocks

Be the first to know about important ZTEK news, forecast changes, insider trades & much more!

ZTEK News

Overview

Due Diligence Score

–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ZTEK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ZTEK ($1.18) is overvalued by 9,106.06% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ZTEK ($1.18) is not significantly undervalued (9,106.06%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ZTEK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ZTEK due diligence checks available for Premium users.

Valuation

ZTEK fair value

Fair Value of ZTEK stock based on Discounted Cash Flow (DCF)

Price
$1.18
Fair Value
$0.01
Overvalued by
9,106.06%
ZTEK ($1.18) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ZTEK ($1.18) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ZTEK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ZTEK price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-13.72x
Industry
39.97x
Market
30.45x

ZTEK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
9.19x
Industry
4.14x
ZTEK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ZTEK's financial health

Profit margin

Revenue
$11.5k
Net Income
-$2.2M
Profit Margin
-19,405%
ZTEK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ZTEK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$15.6M
Liabilities
$2.0M
Debt to equity
0.15
ZTEK's short-term assets ($3.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZTEK's short-term assets ($3.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZTEK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.3M
Investing
-$22.1k
Financing
$2.1M
ZTEK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ZTEK vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ZTEK–$122.80M+20.41%-13.72x9.19x
AKYA–$139.77M+2.17%-2.43x10.25x
PDEXA$144.55M+0.05%28.61x4.68x
ZJYLC$147.20M-4.17%54.12x5.61x
MLSSC$91.91M0.00%-16.86x12.73x

Zentek Stock FAQ

What is Zentek's quote symbol?

(NASDAQ: ZTEK) Zentek trades on the NASDAQ under the ticker symbol ZTEK. Zentek stock quotes can also be displayed as NASDAQ: ZTEK.

If you're new to stock investing, here's how to buy Zentek stock.

What is the 52 week high and low for Zentek (NASDAQ: ZTEK)?

(NASDAQ: ZTEK) Zentek's 52-week high was $1.48, and its 52-week low was $0.50. It is currently -20.27% from its 52-week high and 136% from its 52-week low.

How much is Zentek stock worth today?

(NASDAQ: ZTEK) Zentek currently has 104,064,815 outstanding shares. With Zentek stock trading at $1.18 per share, the total value of Zentek stock (market capitalization) is $122.80M.

Zentek stock was originally listed at a price of $3.40 in Mar 23, 2022. If you had invested in Zentek stock at $3.40, your return over the last 2 years would have been -65.29%, for an annualized return of -41.09% (not including any dividends or dividend reinvestments).

How much is Zentek's stock price per share?

(NASDAQ: ZTEK) Zentek stock price per share is $1.18 today (as of Jan 17, 2025).

What is Zentek's Market Cap?

(NASDAQ: ZTEK) Zentek's market cap is $122.80M, as of Jan 21, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Zentek's market cap is calculated by multiplying ZTEK's current stock price of $1.18 by ZTEK's total outstanding shares of 104,064,815.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.